Previously our study group – together with others - proved that circulating inflammatory biomarkers including C-reactive protein (CRP), fibrinogen and the neutrophil-to-lymphocyte ratio (NLR) are prognostic and – with regard to fibrinogen and CRP – predictive in the setting of multimodality therapy benefit for patients suffering from malignant pleural mesothelioma (MPM)17–20. This evidence concerns the gene CRP and malignant pleural mesothelioma.